Show simple item record

dc.contributor.authorMalekpour-Galogahi, Fariba
dc.contributor.authorHatamian-Zarmi, Ashrafalsadat
dc.contributor.authorGanji, Fariba
dc.contributor.authorEbrahimi-Hosseinzadeh, Bahman
dc.contributor.authorNojoki, Fahimeh
dc.contributor.authorSahraeian, Razi
dc.contributor.authorMokhtari-Hosseini, Zahra Beagom
dc.date.accessioned2021-07-20T23:39:56Z
dc.date.available2021-07-20T23:39:56Z
dc.date.issued2018
dc.identifier.issn0898-2104en_US
dc.identifier.doi10.1080/08982104.2017.1349143en_US
dc.identifier.urihttp://hdl.handle.net/10072/406169
dc.description.abstractRivastigmine hydrogen tartrate (RHT) is a pseudo-irreversible inhibitor of cholinesterase and is used for the treatment of Alzheimer's. However, RHT delivery to the brain is limited by the blood-brain barrier (BBB). The purpose of this study was to improve the brain-targeting delivery of RHT by producing and optimizing rivastigmine hydrogen tartrate-loaded tocopherol succinate-based solid lipid nanoparticles (RHT-SLNs). RHT-SLNs were prepared using the microemulsion technique. The impact of significant variables, such as surfactant concentration and drug/lipid ratio, on the size of RHT-SLNs and their drug loading and encapsulation efficiency was analysed using a five-level central composite design (CCD). The minimum size of particles and the maximum efficiency of loading and encapsulation were defined according to models derived from a statistical analysis performed under optimal predicted conditions. The experimental results of optimized RHT-SLNs showed an appropriate particle size of 15.6 nm, 72.4% drug encapsulation efficiency and 6.8% loading efficiency, which revealed a good correlation between the experimental and predicted values. Furthermore, in vitro release studies showed a sustained release of RHT from RHT-SLNs.en_US
dc.description.peerreviewedYesen_US
dc.languageEnglishen_US
dc.publisherTAYLOR & FRANCIS LTDen_US
dc.relation.ispartofpagefrom226en_US
dc.relation.ispartofpageto235en_US
dc.relation.ispartofissue3en_US
dc.relation.ispartofjournalJournal of Liposome Researchen_US
dc.relation.ispartofvolume28en_US
dc.subject.fieldofresearchPharmacology and Pharmaceutical Sciencesen_US
dc.subject.fieldofresearchcode1115en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsBiochemistry & Molecular Biologyen_US
dc.subject.keywordsPharmacology & Pharmacyen_US
dc.subject.keywordsRivastigmineen_US
dc.titlePreparation and optimization of rivastigmine-loaded tocopherol succinate-based solid lipid nanoparticlesen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationMalekpour-Galogahi, F; Hatamian-Zarmi, A; Ganji, F; Ebrahimi-Hosseinzadeh, B; Nojoki, F; Sahraeian, R; Mokhtari-Hosseini, ZB, Preparation and optimization of rivastigmine-loaded tocopherol succinate-based solid lipid nanoparticles, Journal of Liposome Research, 2018, 28 (3), pp. 226-235en_US
dc.date.updated2021-07-20T23:34:32Z
gro.hasfulltextNo Full Text
gro.griffith.authorMalekpour Galogahi, Fariba


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record